氨基酸转运体在肿瘤代谢中的研究进展

doi:10.19586/j.2095-2341.2021.0016

生物技术进展 ›› 2022, Vol. 12 ›› Issue (1): 50-56.DOI: 10.19586/j.2095-2341.2021.0016

氨基酸转运体在肿瘤代谢中的研究进展

王林琳¹(), 孙振亮²()

^1.上海理工大学健康科学与工程学院，上海 200093
^2.上海健康医学院附属第六人民医院南院中心实验室，上海 201499

收稿日期:2021-01-30 接受日期:2021-06-16 出版日期:2022-01-25 发布日期:2022-01-26
通讯作者: 孙振亮
作者简介:王林琳 E-mail：202562413@st.usst.edu.cn；
基金资助:
国家自然科学基金项目(81872418)

Research Progress of Amino Acid Transporters in Tumor Metabolism

Linlin WANG¹(), Zhenliang SUN²()

^1.School of Health Science and Engineering，University of Shanghai for Science and Technology，Shanghai 200093，China
^2.Central Laboratory，the South Campus of Shanghai No. 6 People，Hospital Affiliated to Shanghai University of Medicine & Health Sciences，Shanghai 201499，China

Received:2021-01-30 Accepted:2021-06-16 Online:2022-01-25 Published:2022-01-26
Contact: Zhenliang SUN

摘要/Abstract

摘要：

代谢重编程是肿瘤的重要特征，是指肿瘤细胞为满足其快速增殖的生物合成与能量需求，对其糖代谢、脂代谢以及氨基酸代谢等代谢路径进行的重编程，以维持增长速度以及补偿能量代谢所造成的氧化还原压力。虽然不同的癌症代谢变化不同，但有些特征是所有癌症共有的，氨基酸代谢重编程是其中一个重要的特征。氨基酸进出细胞需要氨基酸转运体的协助，因而在肿瘤细胞中多种特定的氨基酸转运体均过表达。靶向氨基酸转运体通过影响肿瘤细胞的氨基酸代谢从而达到抗肿瘤的目的，是目前抗肿瘤药物的研究热点之一。主要介绍了几种在肿瘤代谢中发挥重要作用的氨基酸转运体以及靶向氨基酸转运体抗肿瘤治疗的研究进展及相关作用机制，旨在了解氨基酸转运体在抗肿瘤研究中的作用，以期促进靶向氨基酸转运体抗肿瘤药物的发展。

关键词: 氨基酸代谢, 氨基酸转运体, 肿瘤, 靶向治疗

Abstract:

Metabolic reprogramming is an important feature of tumors. It refers to the reprogramming of metabolic pathways such as carbohydrate metabolism， lipid metabolism and amino acid metabolism by tumor cells to meet their rapid proliferation biosynthesis and energy requirements to maintain their growth rate and compensate for the redox stress caused by its energy metabolism. Although different cancers have different metabolic changes， some features are common to all cancers， and amino acid metabolism reprogramming is one of the important features. The transfer of amino acids into and out of cells require the assistance of amino acid transporters， so many specific amino acid transporters are overexpressed in tumor cells. Targeted amino acid transporter achieves the purpose of anti?tumor by affecting the amino acid metabolism of tumor cells， which is also one of the current research hotspots of anti?tumor drugs. This paper mainly introduced several amino acid transporter that play important roles in tumor metabolism and the research progress of anti?tumor therapy and related mechanism， so as to understand the function of amino acid transporters in anti?tumor research， and promote the development of targeted amino acid transporter antitumor drugs.

Key words: amino acid metabolism, amino acid transporter, tumor, target therapy

中图分类号:

R730

王林琳, 孙振亮. 氨基酸转运体在肿瘤代谢中的研究进展[J]. 生物技术进展, 2022, 12(1): 50-56.

Linlin WANG, Zhenliang SUN. Research Progress of Amino Acid Transporters in Tumor Metabolism[J]. Current Biotechnology, 2022, 12(1): 50-56.

参考文献 49

1	BODE B. Recent molecular advances in mammalian glutamine transport[J]. J. Nutr., 2001, 131(9): 2475-2485.
2	GANAPATHY V, THANGARAJU M, PRASAD P D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond[J]. Pharmacol. Ther., 2009, 121(1): 29-40.
3	ZOU Z, TAO T, LI H, et al.. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges[J/OL]. Cell Biosci., 2020, 10: 31[2021-11-01]. .
4	KANAI Y, CLEMENCON B, SIMONIN A, et al.. The SLC1 high-affinity glutamate and neutral amino acid transporter family [J]. Mol. Aspects Med., 2013, 34(2-3): 108-120.
5	GARIBSINGH R A, OTTE N J, NDARU E, et al.. Homology modeling informs ligand discovery for the glutamine transporter ASCT2[J/OL]. Front. Chem., 2018, 6:279[2021-11-03]. .
6	SCALISE M, POCHINI L, GALLUCCIO M, et al. Glutamine transport and mitochondrial metabolism in cancer cell growth[J/OL]. Front. Oncol., 2017, 7: 306[2021-11-01]. .
7	SCALISE M, POCHINI L, CONSOLE L, et al.. The human SLC1A5 ASCT2 amino acid transporter: from function to structure and role in cell biology [J/OL]. Front. Cell Dev. Biol., 2018, 6: 96[2021-11-03]. .
8	BOTT A J, SHEN J, TONELLI C, et al.. Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism[J]. Cell Rep., 2019, 29(5): 1287-1298.
9	LI L, MENG Y, LI Z, et al.. Discovery and development of small molecule modulators targeting glutamine metabolism [J]. Eur. J. Med. Chem., 2019, 163: 215-242.
10	KATT W P, CERIONE R A. Glutaminase regulation in cancer cells: a druggable chain of events [J]. Drug Discov. Today, 2014, 19(4): 450-457.
11	LIU Y, ZHAO T, LI Z, et al.. The role of ASCT2 in cancer: a review[J]. Eur. J. Pharmacol., 2018, 837: 81-87.
12	HASSANEIN M, QIAN J, HOEKSEMA M D, et al.. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer[J]. Int. J. Cancer, 2015, 137(7): 1587-1597.
13	AVISSAR N E, SAX H C, TOIA L. In human entrocytes, GLN transport and ASCT2 surface expression induced by short-term EGF are MAPK, PI3K, and Rho-dependent[J]. Dig. Dis. Sci., 2008, 53(8): 2113-2125.
14	LUO Y, LI W, LING Z, et al.. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells[J]. Cancer Med., 2020, 9(10): 3489-3499.
15	WANG L, LIU Y, ZHAO T L, et al.. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer[J]. Phytomedicine, 2019, 57: 117-128.
16	PALII S S, THIAVILLE M M, PAN Y X, et al.. Characterization of the amino acid response element within the human sodium-coupled neutral amino acid transporter 2 (SNAT2) system A transporter gene[J]. Biochem. J., 2006, 395(3): 517-527.
17	BROER A, RAHIMI F, BROER S. Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells[J]. J. Biol. Chem., 2016, 291(25): 13194-13205.
18	MOROTTI M, BRIDGES E, VALLI A, et al.. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer [J]. Proc. Natl. Acad. Sci. USA, 2019, 116(25): 12452-12461.
19	SAMLUK L, CZEREDYS M, SKOWRONEK K, et al.. Protein kinase C regulates amino acid transporter ATB^(0,+)[J]. Biochem. Biophys. Res. Commun., 2012, 422(1): 64-69.
20	ROGALA-KOZIARSKA K, SAMLUK L, NALECZ K A. Amino acid transporter SLC6A14 depends on heat shock protein HSP90 in trafficking to the cell surface[J]. Biochim. Biophys. Acta. Mol. Cell Res., 2019, 1866(10): 1544-1555.
21	KARUNAKARAN S, RAMACHANDRAN S, COOTHANKANDASWAMY V, et al.. SLC6A14 (ATB^0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer [J]. J. Biol. Chem., 2011, 286(36): 31830-31838.
22	LUO Q, YANG B, TAO W, et al.. (ATB^0,+) transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes[J]. Biomater Sci., 2017, 5(2): 295-304.
23	NALECZ K A. Amino acid transporter SLC6A14 (ATB^0,+)-a target in combined anti-cancer therapy [J/OL]. Front. Cell Dev. Biol., 2020, 8: 594464[2021-11-01]. .
24	KOU L, HUANG H, LIN X, et al. Endocytosis of (ATB^0,+) (SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer [J]. Expert Opin. Drug Deliv., 2020, 17(3): 395-405.
25	CHAFAI A, FROMM M F, KONIG J, et al.. The prognostic biomarker L-homoarginine is a substrate of the cationic amino acid transporters CAT1, CAT2A and CAT2B[J/OL]. Sci. Rep., 2017, 7(1): 4767[2021-11-01]. .
26	HATZOGLOU M, FERNANDEZ J, YAMAN I, et al.. Regulation of cationic amino acid transport: the story of the CAT-1 transporter[J]. Annu. Rev. Nutr., 2004, 24: 377-399.
27	ABDELMAGID S A, RICKARD J A, MCDONALD W J, et al.. CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines [J]. J. Cell Biochem., 2011, 112(4): 1084-1092.
28	PENG J B, ZHUANG L, BERGER U V, et al.. CaT1 expression correlates with tumor grade in prostate cancer[J]. Biochem. Biophys. Res. Commun., 2001, 282(3): 729-734.
29	COBURN L A, SINGH K, ASIM M, et al.. Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis[J]. Oncogene, 2019, 38(7): 1067-1079.
30	SUN T, BI F, LIU Z, et al.. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer[J]. AGING, 2020, 12(13): 13281-13296.
31	KESAVARDHANA S, KANNEGANTI T D. Targeting apoptosis inhibition to activate antitumor immunity[J]. Trends Immunol., 2019, 40(12): 1073-1075.
32	NAVA C, RUPP J, BOISSEL J P, et al.. Hypomorphic variants of cationic amino acid transporter 3 in males with autism spectrum disorders[J]. Amino Acids, 2015, 47(12): 2647-2658.
33	LOWMAN X H, HANSE E A, YANG Y, et al.. p53 promotes cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake[J]. Cell Rep., 2019, 26(11): 3051-3060.
34	JANUCHOWSKI R, ZAWIERUCHA P, ANDRZEJEWSKA M, et al.. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines[J]. Biomed. Pharm., 2013, 67(3): 240-245.
35	ZHAO Y, WANG L, PAN J. The role of L-type amino acid transporter 1 in human tumors[J]. Intract. Rare Dis. Res., 2015, 4(4): 165-169.
36	KOSHI H, SANO T, HANDA T, et al.. L-type amino acid transporter-1 and CD98 expression in bone and soft tissue tumors [J]. Pathol. Int., 2015, 65(9): 460-467.
37	QUAN L, OHGAKI R, HARA S, et al.. Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation[J/OL]. J. Exp. Clin. Cancer Res., 2020, 39(1): 266[2021-11-01]. .
38	DANN S G, RYSKIN M, BARSOTTI A M, et al.. Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2 [J]. EMBO J., 2015, 34(13): 1773-1785.
39	HAFLIGER P, GRAFF J, RUBIN M, et al.. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model[J/OL]. J. Exp. Clin. Cancer Res., 2018, 37(1): 234[2021-11-01]. .
40	FENG M, XIONG G, CAO Z, et al.. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer[J/OL]. J. Exp. Clin. Cancer Res., 2018, 37(1): 274[2021-11-01]. .
41	ARENSMAN M D, YANG X S, LEAHY D M, et al.. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity[J]. Proc. Natl. Acad. Sci. USA, 2019, 116(19): 9533-9542.
42	LIU L, LIU R, LIU Y, et al.. Cystine-glutamate antiporter xCT as a therapeutic target for cancer[J]. Cell Biochem. Funct., 2020, 39(2): 174-179.
43	Sehm T, Rauh M, Wiendieck K, et al.. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis[J]. Oncotarget, 2016, 7(46): 74630-74647.
44	HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
45	SCALISE M, CONSOLE L, ROVELLA F, et al.. Membrane transporters for amino acids as players of cancer metabolic rewiring[J/OL]. Cells, 2020, 9(9): 2028[2021-11-01]. .
46	CHEN Q, ZHOU J, CHEN Z, et al.. Tumor-specific expansion of oxidative stress by glutathione depletion and use of a fenton nanoagent for enhanced chemodynamic therapy[J]. ACS Appl. Mater. Interf., 2019, 11(34): 30551-30565.
47	TANABE A, KIMURA K, TAZAWA H, et al.. Functional analysis of CD44 variants and xCT in canine tumours[J]. Vet. Med. Sci., 2020, 7(2): 577-585.
48	NAKAYA M, XIAO Y, ZHOU X, et al.. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation[J]. Immunity, 2014, 40(5): 692-705.
49	BROER A, GAUTHIER-COLES G, RAHIMI F, et al.. Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells[J]. J. Biol. Chem., 2019, 294(11): 4012-4026.

[1]	董立强, 王斌, 苏适, 刘东琦. 雷公藤红素抗肿瘤作用及机制研究进展[J]. 生物技术进展, 2023, 13(1): 77-82.
[2]	陈小巧, 牧仁, 李玉玲. 脐带间充质干细胞的生物学特性及旁分泌作用的研究进展[J]. 生物技术进展, 2022, 12(4): 559-567.
[3]	王彩虹, 陈剑飞, 鞠久君, 朱雪洁, 王彩霞. PKM2促进肿瘤发展的作用机制研究[J]. 生物技术进展, 2022, 12(3): 411-418.
[4]	肖金平, 李程, 曹云娣, 孙志坚, 康平, 兰晓梅. RET原癌基因与肿瘤相关性研究的进展现状[J]. 生物技术进展, 2022, 12(1): 57-62.
[5]	李征, 郑亚民, 张小农. 镁离子与肿瘤的相关关系[J]. 生物技术进展, 2022, 12(1): 63-67.
[6]	赵鹏翔, 谢飞, 刘梦昱, ADZAVON Yao Mawulikplimi, 马雪梅. 氢气生物医学研究进展[J]. 生物技术进展, 2021, 11(4): 503-517.
[7]	刘程林子,吴耀钦,黄恩泽,徐瑞丰,郑鹏,. 双硫仑抗癌作用研究进展[J]. 生物技术进展, 2021, 11(2): 155-162.
[8]	张迪迪,顾宇轩,孙霄麟,张丽娜. FAM96A和FAM96B结构与功能的研究进展[J]. 生物技术进展, 2021, 11(1): 26-32.
[9]	商蕾,李佳腊,苏泽华,谢飞,马雪梅. 氢分子对肝癌细胞Huh7的影响[J]. 生物技术进展, 2020, 10(4): 400-408.
[10]	刘诗博,吴昊,洪焦,刘梦昱,YAO Mawulikplimi Adzavon,赵鹏翔. 炎症-肿瘤转化在眼部相关疾病中的研究进展[J]. 生物技术进展, 2020, 10(3): 234-241.
[11]	常文婧，赵彦艳. 激光捕获显微切割在肿瘤多组学研究中的应用进展[J]. 生物技术进展, 2020, 10(2): 130-136.
[12]	闫东科,吕平. 低氧诱导因子及其抑制剂研究进展[J]. 生物技术进展, 2019, 9(4): 332-340.
[13]	王婷婷,赵鹏翔,谢飞. 黄芩苷的抗肿瘤作用及机制研究进展[J]. 生物技术进展, 2019, 9(1): 13-20.
[14]	商蕾,李佳腊,苏泽华,谢飞,马雪梅. 氢分子对宫颈癌细胞HeLa的影响[J]. 生物技术进展, 2018, 8(4): 302-310.
[15]	吕宝北,赵鹏翔,张鑫,马雪梅,谢飞. CRISPR/Cas9在肿瘤治疗中的研究进展[J]. 生物技术进展, 2018, 8(3): 191-196.

氨基酸转运体在肿瘤代谢中的研究进展

Research Progress of Amino Acid Transporters in Tumor Metabolism

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 49

相关文章 15

编辑推荐

Metrics

本文评价